Alzheimer’s Disease

Roadblocks to the use of blood-based biomarkers in clinical care

Amyloid prediction models for use in the general population

Increasing participation of underrepresented groups in clinical trials

Visual versus quantitative analysis of tau-PET

Why Alzheimer’s disease research is focusing on tau

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

The promise of tau aggregation inhibitors in dementia

Genes differentially associated with Alzheimer’s disease based on sex and APOE status

Barriers to participation of underrepresented groups in clinical trials

Advantages of tau-PET compared to amyloid-PET

The Phase III LUCIDITY trial: a tau aggregation inhibitor in patients with Alzheimer’s disease

The effect of APOE on the lipidome of individual brain cell types

Fibrin-targeting immunotherapy in Alzheimer’s Disease

Plasma p-tau181 to identify Alzheimer’s disease-related co-pathology in DLB

Recognizing and managing pain in the context of cognitive impairment

Time gap between amyloid- and tau-PET positivity in preclinical disease